Livzon Pharma reports strong profit growth despite slight dip in income

Livzon Pharmaceutical Group Inc. reported operating income of 6,271.91 million yuan for the first half of 2025, a slight year-on-year decrease of 0.17%. Despite this, the company achieved a total profit of 1,828.11 million yuan, representing a substantial 13.66% increase compared to the same period last year. Net profit attributable to shareholders, excluding extraordinary gains or losses, rose by 8.91% to 1,258.46 million yuan.

Basic and diluted earnings per share both increased by 12.60% to 1.43 yuan, up from 1.27 yuan in the previous period. The weighted average return on equity also saw a positive change, increasing by 1.10 percentage points to 9.14%. The company's cash flow from operating activities improved significantly, growing by 10.26% to 1,686,940,768.20 yuan.

The company's R&D investment for the period was approximately 491 million yuan, accounting for 7.82% of total operating revenue, with new product approvals for Aripiprazole microspheres for injection and Progesterone injection. Livzon is also expanding its global footprint, with overseas revenue increasing by 18.40% to 1.004 billion yuan, representing 16.01% of total operating revenue.